Imbruvica

What it is used for

IMBRUVICA is indicated for the treatment of patients with MCL who have received at least one prior therapy.,IMBRUVICA as a single agent is indicated for the treatment of adult patients with Waldenstroms macroglobulinaemia (WM) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy.,IMBRUVICA in combination with rituximab is indicated for the treatment of adult patients with Waldenstroms macroglubulinaemia (WM).,IMBRUVICA as a single agent or in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia/small lymphocytic leukemia (CLL/SLL). Can be used in patients with deletion 17p.,IMBRUVICA as a single agent or in combination with bendamustine and rituximab (BR) is indicated for the treatment of adult patients with chronic lymphocytic leukaemia/small lymphocytic leukemia (CLL/SLL) who have received at least one prior therapy. Can be used in patients with deletion 17p.

How to take it

The way to take this medicine is: Oral. This medicine is taken by mouth.

Store below 30 degrees Celsius
Store in Original Container
Shelf lifetime is 36 Months.

You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.

Always read the label. If symptoms persist see your healthcare professional.

Reporting side effects

You can help ensure medicines are safe by reporting the side effects you experience.

You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems

How to take it

The way to take this medicine is: Oral. This medicine is taken by mouth.

Store below 30 degrees Celsius
Store in Original Container
Shelf lifetime is 36 Months.

You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.

Always read the label. If symptoms persist see your healthcare professional.

Pregnant or planning a pregnancy?

For the active ingredient ibrutinib

You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.

Do I need a prescription?

This medicine is available from a pharmacist and requires a prescription. It is Schedule 4 : Prescription Only Medicine.

Visual appearance

Size 0, white opaque. Hard gelatin capsule with black printing ibr 140 mg

Is this medicine subsidised?

This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on March 1, 2020. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.